Find a Specialist
A bone marrow failure diagnosis of aplastic anemia, MDS and PNH is complicated, and the treatment options require oversight by a well-trained and experienced expert. But, finding an expert can be challenging. AAMDS has…
Graft Versus Host Disease (GVHD)
Transplant and GVHD from the 2025 Chapel Hill Patient and Family Conference
Topic(s)
Bone Marrow Transplant
Presenter(s)
Jeremy A. Meier, MD, PhD
In this recording, Dr. Jeremy Meier discusses the journey of a transplant (before, during and after) and potential management of GVHD.
Cyclophosphamide and Cyclosporin for GVHD Prevention
Original Publication Date
Article Source
External Web Content
Curtis et al. (July 17 issue)1 report evidence of longer graft-versus-host disease (GVHD)–free, relapse-free survival with post-transplantation cyclophosphamide–based prophylaxis than with cyclosporin–methotrexate among patients receiving a stem-cell transplant from a matched…
Understanding Brain Fog, Chemo Brain, with Dr. Jorg Dietrich
Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
Presenter(s)
Jorg Dietrich, MD, PhD
In this webinar, Dr. Jorg Dietrich will discusses the diagnosis of brain fog/chemo brain and how patients can manage this symptom of disease and its treatments.
Advances in Transplant and GVHD with Dr. Corey Cutler
Topic(s)
Bone Marrow Transplant
Presenter(s)
Corey Cutler, MD, MPH, FRCPC
In this webinar, Dr. Corey Cutler discusses advances in transplant and treating GVHD, or Graft Versus Host Disease.
Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study
Original Publication Date
Article Source
External Web Content
Steroid-refractory GvHD (SR-GvHD) following allogeneic transplant is a major clinical challenge and is associated with substantial mortality [1]. While the European Society for Bone and Marrow Transplantation (EBMT) recommends ruxolitinib for second-line treatment of GvHD [2]…
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Original Publication Date
Article Source
External Web Content
Abstract Purpose Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from underrepresented…
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Original Publication Date
Article Source
External Web Content
Key Points Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD. Abstract Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD…
Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management
Original Publication Date
Article Source
External Web Content
Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched…
Pamela Stratton, MD FACOG
Institution
National Institute of Child Health and Human Development
Physician Status
accepting new patients
Primary Disease Area of Focus
Graft Versus Host Disease (GVHD)